Regulating the topological state of DNA is a vital function of the enzyme DNA topoisomerase I. However, when acting on damaged DNA, topoisomerase I may get trapped in a covalent complex with nicked DNA (stalled topoisomerase I), that, if unrepaired, may lead to genomic instability or cell death. Here we show that ADP-ribose polymers target specific domains of topoisomerase I and reprogram the enzyme to remove itself from cleaved DNA and close the resulting gap. Two members of the poly(ADP-ribose) polymerase family, PARP-1 and 2, act as poly(ADP-ribose) carriers to stalled topoisomerase I sites and induce efficient repair of enzyme-associated DNA strand breaks. Thus, by counteracting topoisomerase I-induced DNA damage, PARP-1 and PARP-2 act as positive regulators of genomic stability in eukaryotic cells.
DNA topoisomerase I (topo I)
1 plays an essential role in controlling the level of DNA supercoiling and relieving the torsional stress that is generated during replication, transcription, recombination, and chromatin remodeling (1, 2) . However, when scanning the topological state of DNA, topo I may get trapped in the vicinity of DNA lesions and cause secondary DNA damage by an abortive mechanism (3) . This involves the formation of a DNA single strand break, covalent attachment of the enzyme to the 3Ј-phosphate terminus (cleavage complex), and inhibition of the DNA ligase activity of topo I ("stalled topo I"). Stalled topo I is a threat to genomic stability and cell life, since enzyme-bound nicked DNA can be converted into irreversible single or double strand breaks. In fact, the efficacy of camptothecins, a prominent class of anticancer drugs (also known as topo I poisons) is due to the stabilization of topo I cleavage complexes (4) . In eukaryotes, a specific repair enzyme, tyrosyl-DNA phosphodiesterase 1 (TDP1) has evolved to counteract the secondary DNA damage of stalled topo I by removing the enzyme from the 3Ј-terminus. Nevertheless, a DNA single strand break is generated that needs to be repaired by the base excision repair machinery (5, 6 ).
Here we show that two members of the poly(ADP-ribose) polymerase family, i.e. PARP-1 and PARP-2, can remove stalled topo I from DNA. PARP-1 and PARP-2 belong to the DNA damage surveillance network (7, 8) . They are activated by DNA strand breaks to catalyze the conversion of the respiratory coenzyme nicotinamide adenine dinucleotide (NAD ϩ ) into protein-bound ADP-ribose polymers, with concomitant release of nicotinamide (9) . While PARP-1 has been found to poly(ADPribosyl)ate a number of nuclear proteins ("heteromodification") (Ref. 9 and references therein), both PARP-1 and PARP-2 preferentially modify themselves ("automodification") (10, 11) . We found that, with the attached polymers, PARP-1 and PARP-2 bind to specific domains of topo 1 and reprogram their functions. Even camptothecin-stabilized cleavage complexes, resembling those formed by topo I in the vicinity of DNA lesions (3), could be disjoined by this mechanism.
MATERIALS AND METHODS
Enzymes and Oligonucleotides-Human DNA topoisomerase I, certified to be purified to homogeneity and free of nuclease and topoisomerase II contaminations, was purchased from TopoGen, together with camptothecin and polyclonal anti-human topoisomerase I antibodies.
Recombinant PARP-1 and PARP-2 (Alexis), [␥-32 P]ATP (7000 Ci/mmol) (ICN), and the oligonucleotides (Microsynth) 5Ј-CTAGTAAA-AGACTTGGAAAAATTTTTAAAAAA-3Ј, 5Ј-AATTTTTTTTAAAAATTT-TTCCAAGTCTTTTA-3Ј, 5Ј-CTAGTAAAAGACTTGGA-3Ј, and 5Јp-TT-TTTTAAAAATTTTTCCAAGTCTTTTACTAG-3Ј were of the highest purity commercially available. The sequences of the oligonucleotides are essentially as reported previously (12, 13) . 5Ј-End labeling of the scissile strand oligonucleotide was performed using T4 polynucleotide kinase and [␥- Automodified PARPs and Poly(ADP-ribose)-In the automodification reaction, PARP-1 or PARP-2 were incubated for 30 min with 0.1-0.4 mM [␣-32 P]NAD (4000 dpm/nmol), as described by Beneke et al. (14) . Mock automodification was carried out in the presence of 2 mM 3-aminobenzamide (AB). The products were purified by ultrafiltration on Microcon YM-30 membrane. Automodified or mock-modified enzymes were used freshly for DNA binding/cleavage assays or stored at Ϫ80°C in 50 mM Tris-HCl buffer, pH 7.4, containing 14 mM ␤-mercaptoethanol, 0.5 mM phenylmethylsulfonyl fluoride, 20% glycerol. Free poly(ADPribose) was prepared as described previously (15) and their size distribution determined (16) .
Topo I Reactions-Purified human topoisomerase I (0.5 pmol) was incubated with 32 P-5Ј-end-labeled oligonucleotide substrates (20,000 -40,000 dpm; 20 fmol) in 50 mM Tris-HCl, pH 8.0, including 0.1 mg/ml bovine serum albumin either at 37°C for 10 min or at 30°C for 15 min (suicide substrate). Reactions were carried out in 20 l (final volume) and stopped by adding 0.5 volumes of 3ϫ Laemmli loading buffer. Covalent complexes of topoisomerase I with cleaved oligonucleotides were separated from the uncleaved substrates by 10% SDS-PAGE and visualized by autoradiography. Camptothecin (CPT) was used at 20 M concentration. Autoradiographic bands were quantified by scanning densitometry (Amersham Biosciences); for a representative set of samples, the densitometric quantification of enzyme-bound and free DNA was paralleled by liquid scintillation counting of excised radioactive bands. The fraction of the oligonucleotide substrate in the cleavage complex ranged between 2-5% and 10 -25%, in the absence or presence of CPT, respectively. * This work was supported by the Swiss National Science Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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Poly(ADP-ribose), either PARP-bound or as free polymer, was present in the reaction mixtures at the amounts indicated in the legends to Figs. 1-3 (pmol quantities refer to the ADP-ribose unit); reactions were started by the addition of the radioalabeled oligonucleotide substrates. For reversal experiments, topo I-DNA complexes were allowed to form over 10-min incubation in the conditions described above, then either poly(ADP-ribose) or 0.35 M NaCl (12, 17) were added, and incubation was extended for the time indicated in the legend to Fig. 3 . After SDS-PAGE and autoradiography, the remaining cleavage complexes were quantified by scanning densitometry. For reversal kinetics, the complex formed before any addition was set at 100% and percentage data were plotted on a semilogarithmic scale against time. The religation constant (k r ) was calculated by fitting these data to the equation
Ϫkrt (where C t ϭ percent remaining cleavage complex at the end of the incubation time, t; C 0 ϭ percent cleavage complex at t 0 ϭ 100). k r values were converted to half-life (t1 ⁄2 ) values according to the equation t1 ⁄2 ϭ ln 2/k r (18) .
Binding of topo I to dsDNA was determined by electrophoretic mobility shift (19) . Topo I (45 ng) was incubated with 20 fmol of radiolabeled oligonucleotide, in the conditions described above. At the end of the incubation time, half the reaction mixtures (10 l) were withdrawn, mixed with 0.25 volumes of loading buffer (10 mM Tris-HCl, pH 8.0, 15% Ficoll, 0.05% bromphenol blue), and electrophoresed on native 6% polyacrylamide gel. The remaining half of the reactions was analyzed by SDS-PAGE to evaluate the potential contribution of covalent complexes to the mobility shift. In the conditions used to visualize the noncovalent topo I-DNA complex, the cleavage conjugate was undetectable.
Poly(ADP-ribose) Binding Assay-The noncovalent binding of poly-(ADP-ribose) to topo I (and other proteins) was determined as described previously (20) . Purified proteins were either dot blotted or transferred onto nitrocellulose membrane after electrophoretic separation on 10% SDS-polyacrylamide gel. Bound poly(ADP-ribose) was visualized by autoradiography and quantified by scintillation counting of excised radioactive dots. Western blotted proteins were gold stained using the Protogold staining kit (British BioCell International), as recommended by the manufacturer.
RESULTS AND DISCUSSION

Poly(ADP-ribose) Regulates the Formation of Topo I Cleavage
Complexes-The data in Fig. 1A show that PARP-1 and PARP-2 block the formation of topo I covalent complex with DNA only in the poly ADP-ribosylated form, while the unmodified enzymes, incubated under identical conditions with the inhibitor 3-aminobenzamide (AB), were completely ineffective. Moreover, PARP-1 and 2 were still effective, when topo I complex formation was strongly enhanced in the presence of CPT (Fig. 1A, bottom) but again only after the enzymes had been automodified with ADP-ribose polymers. These data suggested that the ADP-ribose polymers attached to PARP-1 or PARP-2 could be responsible for the inhibitory effects on topo I complex formation. Direct evidence for this is shown in Fig. 1B . Free ADP-ribose polymers detached from PARP-1 or PARP-2 expressed the full inhibitory activity in a dose-dependent manner (Fig. 1B) , while a 4-fold excess (w:w) of a 39-nucleotide singlestranded DNA did not influence the reaction (Fig. 1C, right  panel) . Degradation of polymers to monomeric ADP-ribose, using poly(ADP-ribose)glycohydrolase (PARG), completely abolished the inhibitory principle (Fig. 1C, left panel) .
Poly(ADP-ribose) could prevent the initial DNA binding of topo I, which then would preclude subsequent formation of covalent complexes. Fig. 2A shows that DNA binding, as measured by electrophoretic mobility shift analysis, was not affected by ADP-ribose polymers at quantities up to 20 pmol that completely blocked covalent complex formation (Fig. 1) . Also, ADPribose polymers did not accelerate dissociation of topo I already bound to DNA after a 10 min preincubation (Fig. 2A, lane 5) . On the other hand, 0.35 M NaCl was sufficient to prevent formation of topo I-DNA noncovalent complexes as well as to dissociate them ( Fig. 2A, lanes 4 and 6) . It should be mentioned that in these types of analyses (see also Fig. 2D ) the shifted topo I-DNA complexes always migrated as two discrete bands. The high purity of the topo I preparations (see "Materials and Methods") and the fact that both bands were reduced when incubation was carried on in the presence of anti-topo I antibodies, but not in the presence of nonspecific immunoglobulins (data not shown), argue against DNA binding by protein contaminants. It seems also unlikely that the two complexes result from DNA binding of differently sized topo I fragments. In fact, in Western blot analyses, a single component of the expected molecular weight was detected by polyclonal anti-topo I antibodies ( Fig. 2A, right panel) ; in addition, topo I, either labeled by covalent binding to radiolabeled oligonucleotides (Figs. 1-3) or by noncovalent interaction with [ 32 P]poly(ADP-ribose) (Fig. 4) , migrated as a single band in SDS-polyacrylamide gels. Thus, generation of different conformers of topo I-DNA complexes as well as binding of one or two topo I molecules/oligonucleotide molecule might underlie the peculiar electrophoretic behavior under native conditions. On the other hand, topo I dimers have been shown to form both in vitro (21) and in vivo (22) .
Poly ( of poly(ADP-ribose) could be explained by either inhibition of DNA cleavage (forward transesterification reaction) or by a shift in the cleavage/religation equilibrium in favor of religation (reverse transesterification reaction). To examine whether poly(ADP-ribose) could affect DNA cleavage, the oligonucleotide shown in Fig. 2B was used as a suicide substrate for topo I: in fact the enzyme becomes trapped in the covalent complex (suicide complex), since the cleavage reaction generates a free trinucleotide with the 5Ј-OH end that is lost by diffusion and hence religation becomes impossible (12) . The results of Fig. 2B demonstrate that poly(ADP-ribose) is a potent inhibitor of DNA cleavage by topo I: as little as 1 pmol of polymeric ADP-ribose was sufficient for complete inhibition (Fig. 2B) . Conversely, poly(ADP-ribose) had no effect on preformed suicide complexes (Fig. 2B, compare lanes 1 and 6) . Again, inhibition of DNA cleavage was also achieved with poly(ADP-ribosyl)ated PARP-1 and PARP-2 (Fig. 2, C and D) but not with the unmodified enzymes (Fig. 2C, lanes 4 and 5) . Incidentally, noncovalent topo I binding to the suicide substrate was equally unaffected by poly(ADP-ribosyl)ated PARP-1 and PARP-2 (Fig. 2D) , as has been observed with the reversible cleavage substrate (Fig. 2A) .
Next we determined whether poly(ADP-ribose) could reverse preformed covalent topo I-DNA conjugates by stimulating the religation activity of topo I. In the experiment shown in Fig. 3A , complex formation was allowed to proceed for 10 and 20 min in the absence or presence of camptothecin. Under these condi- 4 and 7) . D, semilogarithmic plot of data from C. The remaining cleavage complexes are expressed as percentage of the complexes formed during 10-min incubation, before any addition (lane 1 in C, control). Reactions were carried on in the presence of CPT. tions, a steady state level of cleavage complexes was reached within 10 min. Following addition of ADP-ribose polymers, the topo I-DNA complexes disappeared (Fig. 3A, lane 3) . Strikingly, this was also observed with the complexes stabilized in the presence of camptothecin (Fig. 3A, lane 6) , indicating that poly(ADP-ribose) is able to overcome the poisoning effect of the drug. Removal of cleavage complexes was achieved with poly-(ADP-ribosyl)ated PARP-1 (Fig. 3B) or PARP-2 (not shown) but not with the unmodified enzymes (Fig. 3B, lane 6) , emphasizing that polymers are essential for this effect. It should be noted that due to the strong inhibition exerted by poly(ADP-ribose) on the DNA cleavage reaction (Fig. 2, B-D) , the disappearance of cleavage complexes in these reversal experiments was essentially dependent on the rate of religation. Uncoupling of cleavage and religation reactions can also be achieved by increasing salt concentration. In fact 0.35 M NaCl blocks cleavage, probably by interfering with de novo binding of the enzyme to DNA (Refs. 12 and 17 and Fig. 2A ) but has no effect on the DNA ligation activity of topo I. The effect of CPT is also reversed under such conditions (17) . A comparison of the religation kinetics in the presence of either poly(ADP-ribose) or 0.35 M NaCl indicated that DNA strand break resealing by topo I is indeed accelerated by poly(ADP-ribose) (Fig. 3, C and D) : the half-life of cleavage complexes was more than 2-fold shorter in the presence of poly(ADP-ribose). Taken together, these results suggest that the low yield of cleavage complexes (Fig. 1) and the efficient reversal of such complexes (Fig. 3) may arise from two opposing actions of poly(ADP-ribose): inhibition of DNA cleavage (Fig. 2) and stimulation of the topo I religation activity (Fig. 3) .
Poly(ADP-ribose) Binds Noncovalently to Topo I-With their long polymeric arms, members of the PARP family can reach out to bind specific proteins (23-25) and alter their domain functions (20, 26) . Several DNA damage checkpoint proteins are targeted in this manner and the mechanism involves one or several poly(ADP-ribose)-binding sequence motifs in the target protein (27) . The motif, a 20 -25-amino acid sequence with regularly spaced hydrophobic residues, interspersed with basic residues and flanking arginines and lysines, was found to occur at three conserved sites in the topo I sequence (Fig. 4A) . These sites are located in structurally and functionally distinct protein domains (28) : two sequences, comprising amino acids 261-280 and 532-550, are in the core DNA-binding domain but at opposite sites of the clamp formed by the enzyme around DNA; a third polymer-binding site (sequence 669 -688) is in the linker domain. The latter connects the DNA-binding and Cterminal domains and has a regulatory role on the overall reaction as it slows down the religation step and thereby facilitates DNA relaxation (18, 29) . Biochemical analysis using a nitrocellulose blot assay (20) directly confirmed that topo I belongs to the family of poly(ADP-ribose)-binding proteins (Fig.  4, B and C) . In the dot blot assay (Fig. 4B) , about 1 pmol of polymeric ADP-ribose/pmol of protein bound to topo I and histone H1 (positive control) immobilized on nitrocellulose. Poly-(ADP-ribose) binding also occurred after electrophoretic separation and Western blotting of these proteins (Fig. 4C) .
Mapping the poly(ADP-ribose)-binding sites into the published crystal structure of human topo I (28) provided a plausible explanation for the differential effects of ADP-ribose polymers on specific domain functions. First, the polymer-binding regions have no primary role in the DNA binding of topo I, which may explain why poly(ADP-ribose), while interacting with the free enzyme (Fig. 4, B and C) , does not affect topo I-DNA noncovalent complexes (Fig. 2, A and D) . On the other hand, the sequence comprising amino acids 532-550 is located into core subdomain III that largely contributes to the formation of the catalytic site: binding of poly(ADP-ribose) at this site may underlie the strong inhibition of the DNA cleavage reaction. The cap region of topo I (residues 175-433), which includes the poly(ADP-ribose)-binding sequence 261-280, is also essential for DNA cleavage (30) .
How poly(ADP-ribose) counteracts CPT action and accelerates DNA religation is less obvious and requires further considerations. The x-ray crystal structures of human topo I in covalent complex with DNA in the absence and presence of a CPT analogue, topotecan, have revealed the mode of binding of the drug and clarified important mechanistic aspects of topo I poisoning (31) . Topotecan binds to the DNA-enzyme complex by intercalating into DNA at the site of cleavage and displacing the nucleophilic 5Ј-OH end of the cleaved strand: thus, religation is prevented. The comparison of the structure of the ternary (enzyme-DNA-drug) and binary (enzyme-DNA) complexes also showed that the most dramatic changes involved the linker domain, which could be visualized in the electron density map only after drug binding. Interestingly, deletion of the linker domain, either total (18) or partial (32), or even a single amino acid substitution (33) make the enzyme insensitive to CPT. Altogether, these observations point to an involvement of this domain in the stabilization of the ternary complex. It should be noted that the linker-associated poly(ADP-ribose)-binding site (amino acids 669 -688) is likely to be the most (if not the only) accessible one to the polymer when topo I is engaged in the cleavage complex. Thus, we speculate that targeting of the linker domain by poly(ADP-ribose) may have a dual effect: (i) it may induce conformational changes that destabilize the CPT binding pocket and reposition the broken DNA strand so that ligation can occur (neutralization of CPT poisoning; Fig. 3) ; (ii) it may alleviate the restrains imposed by the linker domain on DNA religation (18, 29) , which would explain the reduced half-life of cleavage complexes (Fig. 3, C  and D) .
In conclusion, both PARP-1 and PARP-2 are able to disjoin covalent DNA complexes and induce the reversal of DNA breaks that are formed when topo I gets stalled in the vicinity of DNA lesions. DNA breaks are also the activating signal for PARP-1 and PARP-2 (7-11) to produce (ADP-ribose) n-polymers, which we show here to be the molecules responsible for removing topo I from DNA. Thus, an important aspect of PARP-1 and PARP-2 function in preserving genomic stability of cells is to deploy polymers to sites of stalled topo I. By contrast to the topo I removal mechanism catalyzed by tyrosyl-DNA phosphodiesterase 1 (5, 6), this PARP-based rescue mechanism has an immediate impact on the genomic stability of cells, as it is activated within seconds and does not leave an unfilled DNA gap.
Our data also bear on the design of new therapeutic strategies for the treatment of cancers. As shown in Figs. 1 and 3 , poly(ADP-ribose) may counteract the effects of the cancer therapeutic drug camptothecin and contribute to drug resistance. Thus, the efficacy of camptothecin-mimetic drugs can be enhanced by combination with PARP inhibitors. The in vivo relevance supporting this concept has already been demonstrated: cancer cells with compromised PARP-1 function are hypersensitive to camptothecin (34) , and the cytotoxicity of topo I-targeted drugs is enhanced by PARP inhibitors (35, 36) . Finally, the differential effects of poly(ADP-ribose) on particular domain functions of topo I, i.e. the DNA cleavage and ligation reactions, can be exploited by site-specific targeting, and this opens new perspectives for the design of novel topo I-based anticancer drugs.
